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The antiarrhythmic effects of verapamil, 17-monochlor•
acetylajmaline, mexiletine and amiodarone were com•
pared in 14 patients with chagasic myocarditis. Drugs 
and placebo were administered orally in the following 
order: placebo and verapamil, placebo and 17-mono•
chloracetyllYmaline, placebo and mexiletine (1 week each) 
and placebo and amiodarone (4 weeks each). A 24 hour 
ambulatory electrocardiographic recording was ob•
tained after administration of each placebo and drug. 
Verapamil had no effect on the number of ventricular 
premature complexes, ventricular couplets and runs of 
ventricular tachycardia. 17-Monochloracetylajmaline did 
not reduce the number of ventricular premature com•
plexes and ventricular couplets but caused a moderate 
reduction in runs of ventricular tachycardia. Mexiletine 
failed to significantly reduce ventricular premature com-
Amiodarone has recently been shown (1) to be remarkably 
effective against the malignant ventricular arrhythmias oc•
curring in patients with chronic chagasic myocarditis. At 
doses of 600 to 1,000 mg/day, this drug caused total and 
persistent suppression of ventricular couplets and ventricular 
tachycardia and a greater than 93% reduction in the number 
of ventricular premature complexes in 22 of 24 patients 
during a follow-up period of 26.6 months. These results 
were obtained although the ventricular arrhythmias were 
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plexes but caused a moderate decrease in both ventric•
ular couplets and runs of ventricular tachycardia. 
Amiodarone was the only one of the four drugs that 
caused a substantial reduction of ventricular premature 
complexes (logarithmic mean 97.8%; p < O'()()I), total 
suppression of runs of ventricular tachycardia in 11 of 
11 patients and suppression of ventricular couplets in 8 
of 14 patients and a significant reduction in the remain•
ing 6 patients. The much greater efficacy of amiodarone 
as compared with the two sodium channel modifiers (17-
monochloracetylajmaline and mexiletine) and one cal•
cium channel blocker (verapamil) suggests that its potent 
antiarrhythmic activity is probably related to other pe•
culiar and still undefined electrophysiologic and phar•
macologic properties. 
(J Am Coli CardioI1986;7:1114-20) 
commonly associated with sinoatrial dysfunction, severe 
intraventricular block, marked cardiomegaly and heart fail•
ure (2). Under such conditions, it is assumed that other 
antiarrhythmic agents are ineffective or poorly tolerated (1,2), 
but detailed comparative studies are unavailable. In this 
report, we describe the results of a comparative study in 14 
patients with chronic chagasic myocarditis of the effects of 
fourdrugs-verapamil, 17 -monochloracetylajmaline, * mexi•
letine and amiodarone-possessing quite different proper•
ties (3-10). 
Methods 
Study patients. The study group comprised 14 patients. 
The diagnosis of chronic chagasic myocarditis was based 
*17-Monochloracetylajmaline is an ajmaline derivative that may be 
mcluded in group IA of Vaughan Williams' classification (3). Its biologic 
half-life (approximately 6 hours) is longer than that of ajmaline, so it can 
be used in chronic treatments. 
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on previously reported criteria (11). Patients entered the 
study when one conventional electrocardiogram revealed 
ventricular premature complexes showing two or more of 
the following features: multiform ventricular premature 
complexes, R on T phenomenon or couplets or runs of 
ventricular tachycardia. Three or more consecutive ventric•
ular premature complexes were considered ventricular 
tachycardia. 
The main clinical data are summarized in Table 1. Pal•
pitation (12 patients), atypical chest pain (9 patients), dizzy 
spells (4 patients) and moderate dyspnea (4 patients) were 
the most common symptoms. In 12 patients the following 
conduction disturbances were observed: right bundle branch 
block in 8 (with left anterior hemiblock in 5 and left posterior 
hemiblock in 1), incomplete right bundle branch block plus 
left anterior hemiblock in 3 and incomplete right bundle 
branch block alone in 1. In none of these patients could 
either sustained ventricular arrhythmias or cardiac arrest be 
documented. Moderate to severe cardiomegaly was present 
in 10 patients, all of whom exhibited a grossly abnormal 
echocardiogram. None of the patients showed signs of elec•
trolyte imbalance, and none received cardioactive drugs. 
The nature of the study was explained to the patients, and 
informed consent was obtained from all of them. 
Study protocol. After a control 24 hour ambulatory 
electrocardiographic (Holter) recording (445 Avionics 
equipment and two channel recorder), drugs and corre•
sponding placebos were administered, and intratreatment 
Holter recordings were obtained, following the sequence 
illustrated in Figure 1. Veraparnil (320 mg/day in four doses), 
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17 -monochloracetylajmaline (1,200 mg/day in three doses), 
mexiletine (800 mg/day in four doses) and corresponding 
placebos were each given for 1 week. Treatment with amio•
darone (800 mg/day in four doses) lasted 4 weeks and was 
preceded by a placebo period of equal duration. The dif•
ference in duration of treatment was dictated by the fact that 
the first three drugs have a short elimination half-life, rapidly 
reaching a stable plasma concentration (4-7), whereas amio•
darone, whose half-life has been estimated to be about 30 
days (1,9,10), must be administered for a much longer time 
and always as the last drug to avoid a residual effect that 
might alter the results if other drugs were given subse•
quently. 
The eight patients with right bundle branch block were 
subjected to an electrophysiologic study including a His 
bundle recording, atrial overdrive pacing and an ajmaline 
test (12) to exclude the possible occurrence (and risk) of 
latent His bundle or infra-His bundle block. 
Holter analysis of antiarrhythmic treatment. The Holter 
monitor tapes were analyzed automatically by computer 
(model 660 Avionics) to provide the total number of com•
plexes in 24 hours, the maximal, minimal and mean heart 
rate and the total number of ventricular premature complexes 
in 24 hours. The recordings were reanalyzed by two non•
blinded trained physicians, and when discrepancies arose a 
third observer analyzed the tapes. Percent variations 
between observers and automatic count were assessed by 
comparing the number of ventricular premature complexes 
obtained by automatic count and visual monitoring during 
real-time display (5 minutes in each hour of recording). The 
Table 1. Clinical, Electrocardiographic and Radiologic Features in 14 Patients With Chronic Chagasic Myocarditis 
and Ventricular Arrhythmias 
Cardiomegaly on 
Case Age (yr) & Sex Clinical Symptoms Electrocardiogram Chest X-ray* 
42F Palpitation. atYPical chest pam Primary T wave changes 
2 45F AsymptomatIc RBBB;LPH 
3 39M Palpitation IRBBB; primary T wave changes ++ 
4 48M Palpitation, atypical chest pain IRBBB; LAH; primary T wave changes ++ 
5 61M Palpitation, dyspnea, dizzmess RBBB;LAH +++ 
6 36M Palpitation, atypical chest pain RBBB;LAH ++ 
7 30M Palpitation, atypical chest pain RBBB;LAH + 
8 59M Palpitation, dyspnea. dizziness RBBB;LAH +++ 
9 50F Palpitation. dyspnea, dizziness. IRBBB; LAH; primary T wave changes +++ 
atypical chest pam 
10 45F Dyspnea. atypical chest pain RBBB; LVH +++ 
11 33F Palpitation, atypical chest pain RBBB;LAH;LV +++ 
12 42M Palpitation, atYPical chest pam Primary T wave changes; LV ++ 
13 46F Palpitation RBBB; primary T wave changes 
14 59F PalpitatIOn, atypical chest pain. IRBBB; LAH; pnmary T wave changes +++ 
dizziness 
*Extent of cardiomegaly indicated by: - (absent). + (slight). + + (moderate). + + + (severe); F = female; I = incomplete; LAH = left anterior 
hemiblock; LPH = left posterior hemiblock; LV = low voltage; LVH = left ventricular hypertrophy; M = male; RBBB = right bundle branch block. 
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Figure 1. Study protocol. C = control; 17MChAA = 17-mono-
chloracetylajmaline. 
number of extrasystolic foci and the presence of ventricular 
couplets and runs of ventricular tachycardia were established 
from a real-time printout examination of events selected 
during visual monitoring of the tapes. In 10 patients all 
couplets were printed and counted, and in 8 of these the 
same was done for the runs of ventricular tachycardia. Four 
patients had an extremely high and variable number of cou•
plets and three of them also had runs of ventricular tachy•
cardia. The number of couplets and runs of tachycardia in 
these patients could not be accurately counted and is there•
fore referred to as "countless." However, a real-time visual 
Gount of couplets and runs of ventricular tachycardia was 
performed during at least a 3 hour period. Counts greater 
than 2,000 for couplets and 1,000 for runs of ventricular 
tachycardia were obtained by extrapolating the values from 
the 3 hour control period to 24 hours. The shortest coupling 
interval (and occurrence of the R on T phenomenon) was 
measured in strips lasting 1 minute during every hour of the 
recording. 
Statistical analysis. Spontaneous variability of the ven•
tricular arrhythmias. The spontaneous variability was as•
sessed by comparing the numbers of ventricular premature 
complexes, couplets and runs of ventricular tachycardia in 
24 hours of the control recordings with those obtained during 
administration of the various placebos (Fig. 1), applying 
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analysis of variance with two ways of classification (13). 
To attenuate the dispersion, the decimal logarithm (loga•
rithm ventricular premature complex number, couplets, ven•
tricular tachycardia + 1) was used (Fig. 2). 
Evaluation of antiarrhythmic therapy. The number of 
ventricular premature complexes, couplets and runs of ven•
tricular tachycardia on the last day of treatJTleQt with each 
of the four drugs was matched against the corresponding 
variables at the end of each placebo period, using analysis 
of variance. For each one of those variables the logarithmic 
Figure 2. Effects of the four drugs on the number of ventricular 
premature complexes (VPB), couplets and runs of ventricular 
tachycardia (V.T.), expressed in the vertical scale as the decimal 
logarithm. Values during placebo and treatment periods correspond 
to logarithmic mean: I = 10,2 = 100; 3 = 1,000; 4 = 10;000. 
A = amiodarone; M = mexiletine; 17MChAA = 17-mono•
chloracetylajmaline; n.s. = not significant; V = verapamil. 
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Table 2. Ventricular Arrhythmias in Control 24 Hour 
Ambulatory Electrocardiographic Recordings 
Counts 
Frequent VPC (> 30/h) 
No./24 h 2.313 to 26,884 
(mean 7,881 ± 1,776) 
Mean no./h 96 to 1.120 
(mean 328 ± 74) 
Maximal no./h 286 to 1,567 
(mean 733 ± 106) 
Extrasystolic focI 
2':4 
2 
Couplets 
2 to 430 
Countless 
Ventricular tachycardia 
2 to 27 
Countless 
R on T phenomenon None 
VPC = ventricular premature complexes. 
No of Patients 
14 (100%) 
12 (85.7%) 
2 (14.3%) 
10 (71.4%) 
4 (28.6%) 
8 (57.1%) 
3 (214%) 
14 (100%) 
mean of the placebo periods with each one of the treatment 
periods was compared using Tukey's test (test of signifi•
cance of means) (13). 
Results 
Control studies: spontaneous variability. The com•
plexity that characterizes the potentially malignant ventric•
ular arrhythmias of chronic chagasic myocarditis (2) was 
clearly apparent in our study (Table 2). Obviously, criteria 
for selection of our case material favored the inclusion of 
patients with extremely severe arrhythmias. The number of 
ventricular premature complexes, couplets and runs of ven•
tricular tachycardia did not differ significantly with admin•
istration of the various placebos (Fig. 2). These results con-
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firm the persistence and relatively stability of the ventricular 
arrhythmias ocurring in patients with severe chronic cha•
gasic myocarditis (2). 
Antiarrhythmic therapy. Number of ventricular pre•
mature complexes. Table 3 shows the number of ventricular 
premature complexes per 24 hours during administration of 
the four drugs and their corresponding placebos in the 14 
patients. The mean (logarithmic) reduction caused by each 
of the drugs, graphically illustrated in the upper panel in 
Figure 2, was as follows: verapamil, - 30.8% (NS); mex•
iletine, - 52.1 % (NS); 17-monochloracetylajmaline, - 56.4% 
(NS); amiodarone, -97.8% (p < 0.001). Thus, amiodarone 
was the only drug causing a statistically significant reduction 
in the number of ventricular premature complexes. Also, it 
was the only one causing total suppression of the arrhyth•
mias in two patients (Table 3), and a greater than 90% 
reduction of arrhythmias in eight (after 4 weeks of treat•
ment). Of the other three drugs. only mexiletine caused a 
greater than 90% reduction in one patient. 
Ventricular couplets. Table 4 shows the number of ven•
tricular couplets before (placebo) and during treatment with 
the four drugs. In Cases 4, 5. II and 14, the number of 
couplets was countless and never less than 2,000 in 24 
hours. The latter value was arbitrarily utilized for the sta•
tistical analysis. The mean (logarithmic) reduction induced 
by each of the drugs (middle panel, Fig. 2) was as follows: 
verapamil, -18.6% (NS); 17-monochloracetylajmaline, 
-73.6% (NS); mexiletine. - 87.7% (p < 0.01); and amio•
darone. - 98.1 % (p < 0.00 1). Among the four patients 
with a countless number of couplets, verapamil and 17-
monochloracetylajmaline were totally ineffective in all four, 
mexiletine was effective in two and amiodarone was highly 
effective in all four, causing a total suppression of couplets 
in one of them and a large reduction (certainly greater than 
90%) in the other three. 
Table 3. Effects of the Four Drugs on Ventricular Premature Complex (no.l24 h) 
Case Placebo Verapamil a% Placebo Mexiletme a% Placebo 17-MChAA a% Placebo AmlOdarone a% 
16,459 6,883 - 58 22,867 14,526 -36 19,973 16,387 -17 36,100 0 -100 
2 6,768 2,360 - 65 7,070 2,650 -62 8,878 10,296 + 15 9,134 186 98 
3 11,224 11,240 + 0.14 4,147 1,714 -58 6,443 4,230 -34 4,834 1,097 - 77 
4 9,356 8.696 - 7 6,617 2,281 -65 7,840 4,175 -46 7,772 424 - 95 
5 17,881 18,953 + 5 12,902 16,979 +31 11,923 8,678 -59 20,592 567 - 97 
6 3,986 4,722 + 18 5,005 2,299 -54 6,505 1,588 -75 4,444 37 - 99 
7 8,422 5,056 - 39 17,465 8,932 -49 10,252 10,723 + 4 6,225 0 -100 
8 5,171 1,538 - 70 8,144 6,864 -15 7,424 1,590 -78 6,019 76 99 
9 12,685 4,357 - 65 10,032 305 -96 9,436 3,196 -66 5,977 213 96 
10 2,964 1,812 - 38 1,317 2,222 +68 7,150 2,208 -69 21,530 903 96 
II 6,355 6,478 + 2 6,239 3,671 -43 5.126 3,128 -39 5,666 1,353 - 76 
12 3,872 8,423 + 117 3,596 2,556 -29 1,339 922 -31 5,809 840 - 85 
13 3,099 3,471 + 12 4.273 848 -80 1,393 196 -86 2,679 218 - 92 
14 22,499 8,101 -64 4,382 4,480 + 2 25,199 3,340 -86 42,949 17.184 - 60 
X 7,586 5,248 - 30.8 6,456 3,090 -52.1 7,079 3,090 -56.4 8,912 195 - 97.8 
+ = increment; - = reduction; a% = ventricular premature beats/24 h percentage variation; 17-MChAA = 17-monochloracetylajmaline; X = 
loganthmic mean. 
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Table 4. Effects of the Four Drugs on Ventricular Couplets (no.l24 h) 
Case Placebo Verapamll A % Placebo Mexlletine A% Placebo 
I 2 -50 2 5 + 150 5 
2 10 -90 24 0 -100 7 
3 47 150 +219 25 2 -92 18 
6 26 27 +3.8 33 0 -100 430 
7 2 18 +800 30 -97 4 
8 140 10 -93 30 22 -26 253 
9 29 2 -93 19 13 -31 94 
10 137 111 -19 27 17 -37 41 
12 60 86 +43 36 10 -72 12 
13 11 23 +109 23 0 -100 17 
4 * * o * 9 -99 * 
5 * * o * * o * 
11 * * o * -99 * 
14 * * o * * o * 
X 83.1 67.6 - 18.6 81.2 9.9 -87.7 97.7 
*Countless (2,000 or more ventricular couplets). Abbreviations as in Table 3. 
17-MChAA 
o 
3 
17 
3 
2 
25 
o 
36 
4 
o 
* 
* 
* 
* 
25.7 
lACC Vol 7. No 5 
May 1986 1114-20 
A % Placebo AmlOdarone A % 
- 100 10 0 - 100 
-57 28 0 -100 
-6 11 1 -91 
-99 41 0 -100 
-50 60 0 -100 
-90 138 0 -100 
-100 44 4 -91 
-12 16 0 -100 
-66 31 1 -97 
- 100 49 0 - 100 
o * 0 -100 
o * 10 -99 
o * 2 -99 
o * 25 -99 
-73.6 107.1 2 -98.1 
Ventricular tachycardia. Table 5 shows the number of 
runs of ventricular tachycardia observed in II patients be•
fore (placebo) and during treatment with the four drugs. In 
Patients 4, 5 and 14, the number of runs of ventricular 
tachycardia was countless but never less than 1,000 in 24 
hours. Again, the latter value was arbitrarily used for sta•
tistical analysis. The reduction induced by each of the drugs 
(lower panel, Fig. 2) was as follows: verapamil, - 30.9% 
(NS); 17-monochloracetylajmaline, -78.3% (p < 0.05); 
mexiletine, - 86.4% (p < 0.01); amiodarone, 100% (p < 
0.001). Among the three patients with countless runs of 
ventricular tachycardia, verapamil was totally ineffective in 
all three, 17-monochloracetylajmaline was effective in one, 
mexiletine in two and amiodarone in all three. Amiodarone 
was the only drug causing complete suppression of ven•
tricular tachycardia in all II patients (after 4 weeks of 
treatment) . 
patients (28.5%), by 17-monochloracetylajmaline in two 
(21.4%), by mexiletine in 6 (42.8%) and by amiodarone in 
11 (78.5%) of the 14 patients. With arniodarone, these changes 
occurred despite a marked prolongation of the QT interval, 
which was not observed with the other drugs. The number 
of ectopic foci was not reduced by any of the four drugs. 
Amiodarone was the only drug causing a significant change 
in heart rate. After 4 weeks of treatment, the mean heart 
rate was slowed by 10.07 ± 2.44 beats/min (p < O.OI). 
Other effects. A substantial prolongation of the ventric•
ular premature complex coupling interval with suppression 
of the R on T phenomenon was caused by verapamil in four 
Side effects. Periods of marked sinus bradycardia (heart 
rate less than 40 beats/min) or transient sinoatrial block at 
rest or during sleep occurred in II of the 14 patients during 
treatment with verapamil, in 10 with 17 -monochloracetyl•
ajmaline, in 7 with mexiletine and in 8 with amiodarone. 
Transient right bundle branch block developed in four pa•
tients with mexiletine and in three of them it also developed 
with 17-monochloracetylajmaline and amiodarone. No other 
arrhythmogenic effects were noted with any of the four 
drugs. 
Three patients developed congestive heart failure with 
Table 5. Effects of the Four Drugs on Ventricular Tachycardia (episodes/24 h) 
Case Placebo Verapamil 
2 10 1 
3 7 8 
8 8 2 
9 4 3 
10 3 2 
11 2 0 
12 27 28 
13 7 10 
4 * * 
5 * * 
14 * * 
X 28.8 19.9 
A% Placebo Mexiletine 
-90 3 0 
+14 4 0 
-75 12 1 
-25 3 3 
-33 4 2 
-100 4 0 
+4 18 
+43 6 4 
0** 
0*0 
0*3 
-30.9 25.7 3.5 
A% Placebo 17-MChAA 
-100 4 4 
-100 3 0 
-92 3 0 
o 5 0 
-50 10 I 
-100 4 3 
-95 16 5 
-33 8 0 
o * * 
-100 * * 
-99 * 0 
- 86.4 26.3 5.7 
*Countless (;::' 1,000 episodes of ventncular tachycardia). Abbreviations as In Table 3. 
A% Placebo Amiodarone A% 
o 4 0 -100 
-100 10 0 -100 
-100 12 0 -100 
-100 3 0 -100 
-90 3 0 -100 
-25 25 0 -100 
-69 12 0 -100 
-100 3 0 -100 
0*0 -100 
o * 0 -100 
-100 * 0 -100 
-78.3 28.8 0 -100 
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verapamil. 17-Monochloracetylajmaline caused nausea and 
vomiting in three patients, one of whom had to interrupt 
treatment 24 hours before the established date. Mexiletine 
provoked gastrointestinal symptoms in eight patients (in two 
the dose had to be reduced from 800 to 600 mg/day) and 
tremor and dizziness in one. During treatment with amio•
darone, four patients had gastrointestinal problems (in one 
the dose had to be reduced to 200 mg/day the last week of 
treatment; three showed corneal microdeposits and two mild 
photodermatosis) . 
Discussion 
In the present study, verapamil (a calcium channel blocker) 
and mexiletine and 17-monochloracetylajmaline (two 
"modifiers" of the sodium channel) failed to significantly 
reduce the number of ventricular premature complexes in 
14 patients with chronic chagasic myocarditis. In contrast, 
amiodarone induced a mean reduction of 97.8% (p < 0.(01), 
causing total suppression of the ectopic beats in two patients 
and a greater than 90% reduction in eight patients. This 
high efficacy was achieved after 4 weeks of treatment. In 
a previous study (1) in which the effects of amiodarone were 
assessed after much longer intervals (2 to 55 months), the 
efficacy was even greater, resulting in a more than 93% 
reduction in the number of ventricular premature complexes 
in 22 (95.8%) of 24 patients. 
Amiodarone was also the most effective of the four drugs 
in suppressing or reducing the number of couplets and runs 
of ventricular tachycardia. Couplets were totally suppressed 
in 8 of the 14 patients and were reduced by more than 90% 
in the other 6 patients, whereas runs of ventricular tachy•
cardia were totally suppressed in 11 of 11 patients, regard•
less of their frequency before treatment. The other three 
drugs showed some interesting differences. Thus, although 
verapamil proved to be totally ineffective, 17-mono•
chloracetylajmaline caused a moderate decrease in runs of 
ventricular tachycardia, and mexiletine caused a moderate 
reduction of both couplets and runs of tachycardia (Fig. 2). 
These findings seem to support the concept of "therapeutic 
thresholds," according to which there is a first threshold 
for runs of ventricular tachycardia, a second threshold for 
ventricular couplets, a third and even higher threshold for 
maximal reduction or suppression of ventricular premature 
complexes and a fourth and highest threshold for suppres•
sion of multifocal ventricular complexes. In this regard, it 
should be recalled that none of the four drugs was effective 
in reducing the number of ectopic foci, except in the two 
patients in whom amiodarone caused total suppression of 
ventricular premature complexes. 
Mechanism of the antiarrhythmic effects. When this 
study was planned, it was hoped that the choice of drugs 
with different electrophysiologic properties (3) would yield 
data that might shed some light on the mechanism of the 
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arrhythmias. In view of the results, some speculation may 
be warranted. The failure of verapamil to show any antiar•
rhythmic action may suggest that the calcium channel and 
so-called slow responses (14) have little participation, if 
any, in the ventricular arrhythmias (and slow conduction 
and depressed excitability) that are a prominent feature of 
chronic chagasic myocarditis (2,15,16). More difficult to 
interpret were the results obtained with 17 -monochlorace•
tylajmaline (group IA of Vaughan Williams' classification) 
and mexiletine (group IB). Neither drug significantly re•
duced the number of ventricular premature complexes, but 
both showed some effect in reducing the number of couplets 
and runs of ventricular tachycardia. On the other hand, 
amiodarone was highly effective in reducing the number of 
ventricular premature complexes, and was clearly superior 
to the other two drugs in reducing or suppressing couplets 
and ventricular tachycardia; but the three drugs coincided 
in causing or uncovering right bundle branch block (17) in 
a few patients, an event that never occurred with verapamil. 
Altogether, these results suggest that the arrhythmias, 
conduction disturbances and depressed excitability may be 
related to depressed sodium responses, probably caused by 
widespread areas of partial depolarization of the myocardial 
and specific tissues of the heart. A simple hypothesis would 
be that 17-monochloracetylajmaline and mexiletine (5,8), 
as well as amiodarone (18), operate at the level of the sodium 
channel, and that the differences in their efficacy are of a 
quantitative nature. However, a greater depressing effect on 
sodium channel conductance should be accompanied by more 
arrhythmogenic effects and by a greater depression of in•
traventricular conduction, which was not the case with amio•
darone. It seems more likely that a still undefined qualitative 
difference may be the reason for the much greater antiar•
rhythmic potency of amiodarone as compared with that of 
the currently known sodium channel modifiers. 
Limitations. A limitation of the present study was the 
fact that plasma concentrations of the drugs were not avail•
able. However, the doses employed were those known to 
produce concentrations that are effective against other ar•
rhythmias (4,19-22). None of the patients showed severe 
pump failure, hepatic or renal dysfunction (which might 
have altered absorption, metabolism and excretion of the 
drugs). The period of administration of the drugs was greater 
than five half-lives (except for amiodarone), and side effects 
occurred during drug treatment but not during placebo 
administration. 
Conclusions. This study suggests that amiodarone is 
clearly superior to other available drugs for the treatment 
of potentially malignant ventricular arrhythmias in patients 
with severe chronic chagasic myocarditis. This may also 
prove to be true for other forms of cardiomyopathy in which 
ventricular arrhythmias are a prominent feature (23). Chronic 
chagasic myocarditis is frequent in several Latin American 
countries and seems to be a common cause of ventricular 
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fibrillation (24-27). Prophylactic treatment with amioda•
rone may be an effective way of preventing sudden death 
in many patients. Autochthonous cases of acute Chagas' 
disease have been reported in the United States (28-30), 
where a number of immigrants of Latin American origin 
may also be affected by the chronic form of the disease. 
We are indebted to Uhses Questa, MD for computer statistical analysis. 
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